A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Xentuzumab (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 05 Sep 2017 Planned End Date changed from 9 Aug 2017 to 6 Oct 2017.
- 05 Sep 2017 Planned primary completion date changed from 8 Aug 2017 to 6 Oct 2017.
- 10 Jun 2017 Biomarkers information updated